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RESEARCH

Biosimilar Naming Conventions: Pharmacist Perceptions
and Impact on Confidence in Dispensing Biologics
Daniel Tomaszewski, PharmD, PhD

ABSTRACT
BACKGROUND: The approval of the first biosimilar in the United States has
placed increased pressure on the FDA to provide guidance on the naming convention that will be assigned to current and future biosimilars. The
release of the FDA draft guidance on nonproprietary naming of biosimilars
in August 2015 established a naming convention for all biologic products,
including biosimilars. However, the draft guidance is nonbinding while the
FDA continues to receive input from stakeholders, and it does not address
the naming convention that will be used for products designated as interchangeable biologics.
OBJECTIVES: To (a) determine pharmacist perceptions of biosimilar naming
conventions and their impact on confidence to dispense biosimilars and (b)
measure the burden that is created by laws and regulations requiring pharmacists to complete postdispense notifications.
METHODS: A cross-sectional survey of 781 members of the Academy
of Managed Care Pharmacy and the Hematology/Oncology Pharmacy
Association was conducted using an online survey software program.
RESULTS: Participants reported preferring a biosimilar naming convention
that uses a nonproprietary base with a designated suffix (48.1%), compared with the use of a nonproprietary base alone (26.3%), nonproprietary
base plus a prefix (14.2%), or a unique brand name (11.4%). However,
when participants were asked to report their confidence levels when dispensing a biosimilar in place of the reference biologic, more participants
reported high levels of confidence when the products shared the same
nonproprietary name (62.9%). A majority of participants (64.9%) reported
perceptions of increased burden when required to provide a postdispense
notification to prescribers when dispensing biosimilars.
CONCLUSIONS: According to the survey used in this study, pharmacists
prefer the use of a naming convention for biosimilars that includes a nonproprietary proper name with a designated suffix; however, levels of confidence
in substituting a biosimilar for the reference biologic are highest when
products share the same nonproprietary name. In addition, the results of
this study suggest that the naming convention and postdispense notification
requirements may affect the willingness of some pharmacists to dispense
interchangeable biologics. This effect will be minimized if interchangeable
biologics share the same nonproprietary name as the reference biologics.
J Manag Care Spec Pharm. 2016;22(8):919-26
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What is already known about this subject
• In March 2015, the first biosimilar in the United States was
approved by the FDA.
• Despite draft guidance issued by the FDA, specific biosimilar
naming conventions remain undefined.
• The confidence of pharmacists to dispense an interchangeable
biosimilar is higher when the biosimilar and reference biologic
share the same nonproprietary name.

What this study adds
• Survey results showed that pharmacists preferred a biosimilar
naming convention that included the nonproprietary name with
a designated suffix.
• Pharmacists reported that the type of naming convention
affected their confidence in substituting biosimilars for the reference biologic.
• Study results showed that reporting requirements affected the
willingness of some pharmacists to dispense interchangeable
biologics.

T

he passage of the Drug Price Competition and Patent
Term Restoration Act of 1984, also known as the
Waxman-Hatch Act, created an abbreviated approval
process for small molecule products based predominantly on
the ability of generic manufacturers to demonstrate bioequivalence with the reference product.1 The primary purpose of the
Waxman-Hatch Act was to expedite the availability of generic
drugs so as to increase price competition between branded
reference products and less costly generics. This act has been
widely successful at creating the intended competition, which
has resulted in significant cost savings for small molecule
drugs.1 The abbreviated approval process contained in the act,
however, cannot be used for biologic agents, since demonstrating bioequivalence was deemed insufficient for such large
molecule products.
Before 2009, all prescription drugs produced using biotechnology were required to receive approval from a single U.S.
Food and Drug Administration (FDA) application process,
known as the Biologic License Application (BLA) pathway,
which required manufacturers looking to market follow-on
products after patent expiration to complete the same, fullapproval process as the reference product manufacturer.2 This
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requirement left most manufacturers of biologic prescription
drugs immune from likely competition from potential followon products because of the need for manufacturers to complete
the same lengthy and expensive approval process as the reference biologic.
The inclusion of the Biologics Price Competition and
Innovation Act of 2009 (BPCIA) into the Affordable Care Act
and its passage into law created a new abbreviated approval
process for follow-on biologics. Follow-on biologics have
since become more commonly known as biosimilars and interchangeable biological products and will be referred to here as
“interchangeables.”3 This abbreviated pathway substantially
shortened the approval times and reduced the size and length
of required clinical trials compared with the standard BLA
process and is focused on the ability of manufacturers to show
no clinically significant differences in the chemical makeup of
the product or safety and efficacy outcomes. The inclusion of
a pathway for approving interchangeable products has yet to
be defined by the FDA, and guidance for the requirements for
approval of these products has not yet been published.
A biosimilar is defined as a biologic agent that is highly similar to the reference product notwithstanding minor difference
in clinically inactive components.4 This definition explicitly
states that it is not expected that biosimilar manufacturers will
be able to create an exact replica but, rather, will produce biologic agents that closely enough resemble the reference product
to elicit a response that is clinically the same as the reference
product.5 This acceptable variance in the clinically inactive
components of these products has been deemed required based
on the complexity of the production process of biologics and
the complexity of the biologic agents themselves.6
Following the enactment of the BPCIA legislation into
law, limited guidance on the approval process and marketing of biosimilars existed.5 In May 2014, the FDA released its
initial draft guidance that outlined the approval process and
exclusivity standards. In July 2014, the FDA accepted its first
biosimilar application, and in March 2015, the first biosimilar
was approved by the agency.8 With 1 biosimilar approved,
additional applications under review, and an anticipated large
number of approvals in the works, several details remained
undefined from the original law, including the naming convention that will be used to reference approved biosimilars and
interchangeable products.9 Following completion of the data
collection phase of this project, the FDA released draft guidance and a proposed rule on naming conventions for biosimilars and biologics in August 2015.10
Historically, small molecule products have relied on a nonproprietary, active ingredient (generic) name assigned by the
United States Adopted Names Council to reference the original
reference product and subsequent generics.11 This naming
structure is intended to establish that products from different
manufacturers with the same active ingredient may contain
different inactive compounds, but the active component of the
product is the same.11
920 Journal of Managed Care & Specialty Pharmacy

JMCP

August 2016

Initially, biologics and the first approved biosimilar worldwide were named using a process much the same as small molecules.12 Biologics were assigned a nonproprietary name based
on the active compound, and all future products that shared
the same active compound (i.e., protein structure) would share
the same nonproprietary name. This approach was altered,
however, with the first FDA-approved biosimilar in the United
States. The approval of Zarxio, a biosimilar for Neupogen,
initially entered the market using a unique trade name with
a nonproprietary name that included a base active ingredient
name plus a suffix related to the manufacturer’s name, that is,
filgrastim-sndz.13
This naming convention was altered with the release of the
FDA draft guidance on biosimilar naming in 2015.10 This draft
guidance recommends that all previously approved, currently
under review, and future biosimilars and current and existing
reference biologics be named based on a nonproprietary name
with an assigned hyphenated suffix.10 The FDA’s draft guidance
reported the intent to designate each approved biologic with a
nonproprietary name, including a randomly assigned 4-letter
suffix that is devoid of meaning.10 The current draft guidance
does not detail the naming requirements for any future biologics
that are approved as an interchangeable biologic from the FDA.
The FDA’s draft guidance cited the need for improved pharmacovigilance and to clearly differentiate all products that
are not deemed interchangeable as the rationale for assigning
unique suffixes to each unique biologic.10 Those supporting
the use of a unique biologic qualifier or unique overall name
for biosimilars cite the importance of using the unique product
names to better track patient- and health care provider-reported
adverse events.14 Supporters state that using the same nonproprietary name for biosimilars could result in confusion in the
reporting process and make pharmacovigilance studies more
difficult and inaccurate. Opponents cite the presence of unique
identifiers, such as National Drug Code (NDC) numbers and
lot numbers, as reasons why assigning a suffix or other biologic
qualifier or unique product name is not necessary. Opponents
also cite the potential to create confusion among providers
and patients.14 However, data from the FDA Adverse Event
Reporting System have suggested an adverse-reporting trend
toward continued adverse reports being assigned to the brandname reference product even after a shift in market to primarily
using generic products.15
In a previous study that focused on determining the naming
preference of biosimilars, pharmacists reported higher levels of
confidence when substituting an interchangeable product for
the reference product, if each product shared the same nonproprietary (proper) name.16 In addition, pharmacists reported
substantially lower levels of confidence if the interchangeable
was assigned a unique, proprietary name or a nonproprietary
name with either a prefix or suffix.16
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TABLE 1

Key Demographics of Study Participants

Employment type
Managed care organization
Hospital
Manufacturer
Large chain pharmacy (>10 pharmacies)
Academia
Outpatient clinic (dispensing)
Specialty pharmacy
Outpatient clinic (nondispensing)
Independent pharmacy
Mail order pharmacy
Small chain pharmacy (4-10 pharmacies)
Other/not reported
Perceived knowledge of biologics
Expert
Highly knowledgeable
Generally knowledgeable
Perceived lack of knowledge
Dispenses biologics
Yes
No
General demographics
Age, in years, mean [SD]
Years in practice, mean [SD]
SD = standard deviation.

%

(n)

29.8
15
10
5.4
4.9
4.7
3.3
2.4
1.8
1.1
0.5
21.2

(233)
(117)
(78)
(42)
(38)
(37)
(26)
(19)
(14)
(8)
(4)
(165)

4.7
29.1
49.8
16.3

(37)
(227)
(388)
(127)

50.2
49.8

(391)
(389)

42.7
16.7

[12.7]
[12.3]

The primary objective of this study was to determine
pharmacist perceptions regarding biosimilar naming and the
impact of the naming convention used for interchangeables on
pharmacist willingness to dispense interchangeables. The secondary objective of this study was to measure the anticipated
burden that is created by laws and regulations requiring pharmacists to complete postdispense notifications to prescribers
after dispensing an interchangeable biologic. The results of
this study will help shape the continuing discussion concerning biosimilars and the laws and regulations that govern them.
■■ Methods
This study was conducted using a cross-sectional survey that
collected data from May 2015 to June 2015. A web-based,
electronic survey was distributed through e-mail and was conducted using the electronic survey engine Qualtrics. This study
was reviewed and approved by the Internal Review Board at
Chapman University (IRB #1415H152).
Participants were members of the Academy of Managed
Care Pharmacy (AMCP) and Hematology/Oncology Pharmacy
Association (HOPA) who reported their e-mail addresses to
their respective associations. For inclusion in the survey,
participants needed to maintain a pharmacist membership
with either association. Exclusion criteria were as follows: the
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removal of student memberships, members without an email
address reported, or those holding nonpharmacist membership. Potential participants were e-mailed an invitation to the
survey, followed by up to 2 reminder e-mails if they did not
complete the survey. A total of 10,673 invitation e-mails were
sent, of which 485 e-mails were returned as undeliverable,
blocked, or unsubscribed, and an additional 11 respondents
requested to be removed from the study. This left 10,177 surveys assumed to have been delivered.
The survey instrument was developed by modifying and
adding additional items to an earlier survey that measured
pharmacist perceptions of biosimilars.14 Additional items
included those focused on determining the participants’ naming preference for biosimilars, level of burden that postdispensing requirements are likely to cause, and whether participantreported dispensing of biologics occurred at their place of
employment.
Measures
Survey items focused on pharmacist perceptions primarily used
a 5-point Likert scale. These items varied from asking pharmacists to rank their overall knowledge of biosimilars, with 1
equating to “I know nothing about biosimilars” and 5 equating
to “I consider myself an expert on biosimilars.” Questions measuring level of confidence were scored with 1 equating to “Not
confident at all” and 5 equating with “Very confident.” Survey
items asking participants to rank their confidence based on
naming convention included an additional option of “The name
of the product would not impact my confidence.” Those choosing this option were removed from the analysis. Participants
were also asked to choose from a list of potential naming
conventions for hypothetical biosimilars in order to share their
most preferred and least preferred naming structure.
Comparison of confidence-level reporting was completed
using the Wilcoxon signed-rank test between the naming convention with the highest confidence reported (nonproprietary
name only) with each possible other naming convention. In
addition, a chi-square test comparing the differences between
the nonproprietary name only naming convention with each
additional naming convention was conducted using the 5 confidence categories, as well as an analysis based on 2 categories:
confident (combination of very confident and moderately confident) and not confident (combination of somewhat confident,
minimally confident, and not confident at all). Use of the highest rated confidence naming convention as the reference for statistical analysis allowed for more concise reporting of statistical
analysis. Chi-square tests were used to also analyze for potential differences in naming preference between those who were
employed at a site that dispensed biologics compared with those
who were employed at a site that did not dispense biologics.
The survey also requested information related to the tracking and reporting process. In addition, participants were asked

August 2016

JMCP

Journal of Managed Care & Specialty Pharmacy 921

Biosimilar Naming Conventions: Pharmacist Perceptions and Impact on Confidence in Dispensing Biologics

TABLE 2

Reported Preference of Biosimilar Naming Convention by Employment Type

Nonproprietary Only
Nonproprietary Plus Suffix Nonproprietary Plus Prefix
Employment Type
%
(n)
%
(n)
%
(n)
Hospital (n = 116)
17.9
(21)
44.4 (52)
29.1 (34)
29.8 (37)
45.2 (56)
13.7 (17)
Outpatient pharmaciesa (n = 124)
Specialty pharmacy (n = 26)
38.5
(10)
34.6
(9)
19.2
(5)
MCOs (n = 233)
31.3 (73)
50.2 (117)
6.9 (16)
Manufacturer (n = 78)
16.7 (13)
50.0 (39)
15.3 (12)
Academia (n = 37)
21.6
(8)
43.2 (16)
29.7
(11)
Other/unreported (n = 139)
25.9 (36)
52.5 (73)
8.6 (12)
Total
26.3 (198)
48.1 (362)
14.2 (107)
a Includes those reporting independent, small chain, large chain, clinic nondispensing, and clinic dispensing.
MCO = managed care organization.

TABLE 3

Unique Brand Name
%
(n)
7.7
(9)
11.3 (14)
7.7
(2)
11.6 (27)
17.9 (14)
5.4
(2)
12.9 (18)
11.4 (86)

Reported Least Preferred Biosimilar Naming Convention by Employment Type

Nonproprietary Only Nonproprietary Plus Suffix Nonproprietary Plus Prefix
Employment Type
%
(n)
%
(n)
%
(n)
Hospital (n = 116)
37.6 (44)
4.3
(5)
20.5 (24)
20.3 (25)
15.5 (19)
26.0 (32)
Outpatient pharmaciesa (n = 122)
Specialty pharmacy (n = 26)
26.9
(7)
19.2
(5)
26.9
(7)
MCOs (n = 233)
18.0 (42)
4.3 (10)
30.5 (71)
Manufacturer (n = 78)
39.7 (31)
7.7
(6)
25.6 (20)
Academia (n = 37)
23.7
(9)
10.5
(4)
5.2
(2)
Other/unreported (n = 139)
19.5 (32)
5.5
(9)
23.3 (38)
Total
25.4 (190)
7.7 (58)
25.9 (194)
a Includes those reporting independent, small chain, large chain, clinic nondispensing, and clinic dispensing.
MCO = managed care organization.

to report how these data were stored and (when applicable)
shared with the prescriber. Only participants who reported
dispensing biologics at their place of employment were
displayed these questions. Finally, demographic questions
included employment type, participation in the dispensing
process of prescription drugs, likelihood to dispense biosimilars at current practice, years in practice, age, and state of
primary practice.
■■ Results
A total of 924 participants (9.1% of assumed delivered invitations) clicked on the link to start the survey. Of those, 851
participants responded to the first question on the survey;
however, 70 of those participants completed less than 50% of
the survey. Participants completing less than 50% of the survey
were eliminated from the analysis, which left 781 participants
whose data were included in the survey (response rate = 7.7%
and relative completion rate = 84.5%). Not all participants
answered all questions, since responding to each question
was voluntary. Also, the survey was adaptive, and a number of
items were dependent on responses to other questions, resulting in selected items not being displayed to all participants.
922 Journal of Managed Care & Specialty Pharmacy
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Unique Brand Name
%
(n)
36.8
(43)
37.4
(46)
26.9
(7)
46.8 (109)
25.6
(20)
60.5
(23)
36.0
(59)
40.9 (307)

The demographic composition of the survey participants is
shown in Table 1. The distribution of pharmacists by employment type is similar to that expected based on the e-mail
databases that served as the sole means of survey distribution.
The majority of participants reported having at least a general
knowledge of biosimilars (83.7% rated themselves as generally
knowledgeable or higher). Half of the participants (n = 391,
50.2%) reported dispensing biologics at their place of employment, and 389 participants (49.8%) reported that biologics
were not dispensed at their place of employment.
Overall naming preference is reported in Table 2. Participants
were asked their preferences for the naming convention to be
used for biologic products approved by the FDA as a biosimilar.
Results show that participants reported a preference (48.1%
overall) for the naming convention that used the nonproprietary (active ingredient) name plus suffix. This preference
was also reported by managed care organizations (50.2%)
and hospital pharmacists (44.4%). All employment sectors
reported a preference for the nonproprietary name plus suffix,
except those practicing in specialty pharmacy, who expressed
a preference for using strictly the nonproprietary name (38.5%
preferred active ingredient only and 34.6% preferred active
ingredient plus suffix).
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FIGURE 1

Naming Preference Dependent on Reports of Dispensing Biologics (N = 752)

60

50.9

Percentage

50

45.3

40
30

26.0

26.6
17.9

20

10.7

10
0

Nonproprietary Only

Nonproprietary Plus Suffix

Nonproprietary Plus Prefix

Biosimilar Name Perference

Dispenses Biologics (N = 369)

10.8

11.7

Unique Brand Name

Does Not Dispense Biologics (N = 383)

Note: There is no statistically significant difference between the Dispenses Biologics group and the Does Not Dispense Biologics group according to the Pearson
chi-square test (P = 0.082).

Those participants reporting preferences for the nonproprietary name plus suffix preferred the use of a suffix tied to
the manufacturer name (83.4%), compared with the random
assignment of a 4-letter suffix (16.6%). Nonproprietary (active
ingredient) name only was the second most preferred naming
convention, with 26.3% of participants selecting it. Overall, the
least preferred naming conventions included the use of unique
brand names and the use of a nonproprietary names plus a prefix
(Table 3). Hospital pharmacists and pharmacists representing
academia preferred the use of a prefix plus nonproprietary name
(29.1% and 29.7%, respectively) over the nonproprietary name
only convention (17.9% and 21.6%, respectively; Figure 2).
A total of 383 participants who responded to these survey
items indicated that they did not dispense biologics at their
place of employment, and 369 participants reported dispensing biologics. Figure 1 shows naming preferences of those
participants who worked at a pharmacy that dispensed biologic agents, compared with those participants who did not
work at a pharmacy that dispensed biologics. Naming convention preference here remained with the active ingredient
plus a suffix (45.3% and 50.9%, respectively), and based on a
chi-square analysis (P = 0.082), no distinguishable difference
existed between those dispensing biologics, suggesting that the
involvement in the dispensing of these products did not affect
the overall naming preferences.
Although pharmacists reported a preference for the use of
a naming convention that included the nonproprietary name
plus a suffix for biosimilars overall, when asked to rank their
confidence in dispensing an interchangeable biosimilar based
on naming conventions, the use of a nonproprietary name only
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was related to highest levels of confidence, with 62.9% of participants reporting “very confident” or “moderately confident”
when substituting an interchangeable (chi-square analysis
between confident and not confident responders based on
naming convention, P < 0.001; Figure 2). When asked to rank
confidence levels when using a nonproprietary name plus a
suffix, 57.4% of participants reported being confident. Use
of a nonproprietary name plus a prefix was associated with
53.8% of participants being confident, and the use of a unique
brand name was associated with 53.7% of participants being
confident. In addition, when comparing confidence based on
the assigned 5 categories of confidence, the nonproprietaryonly naming convention remained associated with more participants reporting higher levels of confidence (P < 0.001). A
Wilcoxon signed-rank test further demonstrated that the use
of a nonproprietary-only name was related to higher levels of
confidence when compared with all other naming conventions
(P < 0.001 across all comparisons).
Participants who reported that biologics were dispensed at
their place of employment were asked to share what productrelated data were collected and stored when dispensing biologics.
Based on participants who reported this information (n = 357),
77.9% (n = 278) reported recording NDC numbers related to
the product dispensed. Of those who reported that NDC numbers were not recorded (n = 79), 32.9% (n = 26) reported that
they recorded a combination of J-code or Healthcare Common
Procedure Coding System codes or the nonproprietary name
and the manufacturer. Of those participants who reported
that NDC numbers were not reported (n = 79), 18.1% (n = 14)
reported that they were unaware of what data were recorded.
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FIGURE 2

Confidence of Pharmacists in Dispensing an Interchangeable Biologic Based on Naming
Convention Use (N = 619)

Percentage

40
30
21.8

20
10
0

6.5 6.4

7.3

7.4

Not Confident At All
Nonproprietary Onlya

8.8 10.3

25.9 26.0 25.8

30.0 30.4 28.1 29.5

33.0
27.0 25.7
24.2

12.8 13.0

Minimally Confident

Somewhat Confident

Nonproprietary Plus Suffix

Moderately Confident

Nonproprietary Plus Prefix

Very Confident

Unique Brand Name

aChi-square test comparing confident responders for nonproprietary only naming nomenclature with all other forms of naming conventions showed differences for all
comparisons (P < 0.001). Similarly, chi-square testing showed difference based on the use of all 5 confidence reporting categories (P < 0.001). Wilcoxon signed-rank test
analysis results demonstrated that nonproprietary name only demonstrated a statistically significant increase in confidence over other naming conventions (P < 0.001).

This left 10.9% (n = 39) of participants who reported potentially
insufficient data to determine which product was dispensed.
Participants were also asked how they recorded these data,
and responses primarily included barcode scanning (33.5%),
typing product name into an electronic prescription record
(24.8%), and selecting the product in a drop-down window
(21.7%). A total of 46.5% of participants reported that some or
all of this recorded information was shared with the prescribers. The remaining participants were split between reporting
that no data were shared (24.2%), unsure if any data were
shared (8.7%), and nonresponders (20.6%).
Finally, participants were asked to report the level of burden they perceived if they were required to provide a postdispensing notification to prescribers whenever a biosimilar was
dispensed (Figure 3). A majority of participants reported some
to substantial burden (64.8%) resulting from such a requirement. When asked if a postdispensing reporting requirement
would affect their likelihood of dispensing a biosimilar, many
reported that it would not have an effect (44.4%). In addition,
27.7% participants stated that it would make them less likely
to dispense a biosimilar or were unsure of its effect currently
(24.3%; Figure 4).
■■ Discussion
The nonproprietary name plus a suffix was the biosimilar naming convention most preferred by pharmacists completing the
survey used in this study. Although pharmacists did report a
preference for using a nonproprietary name plus a suffix for
biosimilars, they did not demonstrate increased confidence
when dispensing an interchangeable biologic using this naming convention. Higher levels of confidence were reported
924 Journal of Managed Care & Specialty Pharmacy
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when the interchangeable product shared the same nonproprietary name with the reference biologic.
Because pharmacists reported that they are more confident substituting interchangeables when products share the
same nonproprietary name, the use of a unique name for each
interchangeable may reduce pharmacist confidence in dispensing products using other naming conventions. It is, however,
unclear from the information gathered in this study what effect
lowered pharmacist confidence would have on the dispensing
and use of interchangeables, but the results of this study suggest that using the nonproprietary name only as the naming
convention for interchangeables could have a positive effect on
pharmacist attitudes.
Responses to questions regarding the recording of data suggest that NDC numbers are the most reported product specific
information recorded at the time of dispensing. NDC numbers
are product specific and allow for pharmacovigilance tracking
similar to that of assigning a unique suffix to each product. To
further demonstrate the frequent use of NDC numbers, participants reported recording nonproprietary names less frequently
than NDC numbers (70.5% vs. 77.9%). These responses suggest that the inclusion of a suffix may not achieve the goals
outlined by the designation of a suffix.
As states consider enacting laws requiring pharmacists
to complete either predispense or postdispense reporting to
prescribers when dispensing a biosimilar, legislators and regulators should consider potential increased burden on pharmacists and what value this will bring to the patient. The results
of this study suggest that many pharmacists believe such
requirements are adding burden, and many may be less likely
to substitute approved interchangeable biosimilars, if required
to complete postdispense reporting.
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FIGURE 3

Pharmacist-Reported Level of Burden
Associated with Postdispensing
Notification Requirements When
Dispensing a Biosimilar (N = 381)

FIGURE 4

Effect of Likelihood to Dispense
Biosimilar If Postdispensing Notification
to Prescriber Is Required (N = 383)

6.3%
11.0%
24.3%
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Some Burden

Not Sure of Impact

Substantial Burden
Not Sure of Burden

Unfortunately, no research has been conducted as to how
prescribers will use this information or how such data will be
incorporated into patient medical records. The current proposed bills and already enacted state laws requiring pre- or
postdispensing reporting do not require prescribers to share
any clinical information with pharmacists. In addition, the laws
generally do not require prescribers to maintain the information
that is provided. These one-sided communication requirements
do not promote team-based care and lack reporting requirements that will help inform pharmacists as to whether patients
may benefit from the dispensing of a specific product.
Limitations
There are limitations to this study that need to be considered.
First, the methods used to initiate this survey limited responses
to pharmacists who were members of HOPA or AMCP at the
time of the survey launch, which limits the generalizability
of the study to pharmacists as a whole. Second, the survey
was conducted as a single cross-sectional study, which does
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not allow for longitudinal analysis of pharmacist perceptions
related to biosimilars. Third, the methods used to deliver the
e-mail invitation to the survey did not allow for survey receipt
tracking. Response rates were based on the assumption that all
e-mails not rejected or returned were delivered to the intended
recipient. The use of e-mail tracking and receipt confirmation
would have helped to define which invitees actually received
the survey. Finally, the use of a close-ended online survey
limited the ability of participants to provide researchers with
additional information related to the rationale for the responses
provided in the survey.
■■ Conclusions
The results of this study update the preferences and perceptions of pharmacists regarding biosimilars from previous
studies. The findings are intended to show regulators and
legislators the importance of establishing a naming convention
that encourages acceptance of biosimilars in the United States,
as well as offers the necessary safety and pharmacovigilance
tracking to ensure proper use. Regarding biosimilar naming
conventions, participants in this study reported a preference for
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using the nonproprietary name plus a suffix; however, pharmacist confidence levels in substituting an interchangeable
product with the reference biologic were highest when both
products shared the same nonproprietary name. This finding
suggests that, as biosimilars are considered by the FDA for
approval with the designation as interchangeables, it may be
beneficial for these products to share the same nonproprietary
name. If such a naming convention is not adopted, additional
efforts may be required to ensure that the dispensing pharmacists are conveying appropriate information to patients who
will be using these products.
The potential requirement for pharmacists to provide
postdispensing notification to prescribers after dispensing a
biosimilar or interchangeable product was reported by survey
participants to place increased burden on dispensing pharmacists. Such requirements need to be evaluated to determine
their usefulness, and states that do implement these requirements need to evaluate their effects during implementation.
This evaluation should include the potential effects on the willingness of pharmacists to dispense interchangeable products,
prescriber use of the reported information, and the increased
workload that these requirements create.
This project suggests the need for continued provision of
educational support for pharmacists who are involved with
biologics, biosimilars, and interchangeable biologics. Although
pharmacists report a general knowledge of these products,
there remain varying opinions and knowledge levels across
the profession. It is vital that pharmacists have the necessary
knowledge and expertise in this area so that they can take their
place as medication experts within the health care team.
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